DCTH Stock Analysis: Buy, Sell, or Hold?
DCTH - Delcath Systems Inc
$11.02
-0.43 (-3.76%)
▼
5d:
-0.45%
30d:
+3.57%
90d:
+13.14%
BUY
MODERATE Confidence
Analysis Updated: May 22, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When DCTH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DCTH shows positive signals but monitor for confirmation. Market pricing in 0% growth. Moderate conviction.
💡 BUY OPPORTUNITY: DCTH shows positive signals but monitor for confirmation. Market pricing in 0% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DCTH is currently trading at $11.02, which is considered fair relative to its 30-day fair value range of $10.67 to $11.36. From a valuation perspective, the stock is trading at a discount (Forward PE: -28.8) compared to its historical average (48.5). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, DCTH is in a uptrend. The price is currently testing key support at $10.71. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.29 (+93.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DCTH is in a uptrend. The price is currently testing key support at $10.71. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.29 (+93.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$10.67 -
$11.36
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 93.2% below Wall St target ($21.29)
Trading Range Analysis
30-Day Trading Range
$10.67 -
$11.36
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.12
(10.2%)
Support & Resistance Levels
Support Level
$10.71
Resistance Level
$11.72
Current Trend
Uptrend
Technical data as of
May 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-28.75
Wall Street Target
$21.29
(+93.2%)
Revenue Growth (YoY)
26.3%
Earnings Growth (YoY)
-66.7%
Profit Margin
0.6%
PE vs Historical
-28.8 vs 48.5
CHEAP
Share & Embed Analysis
Last updated: May 25, 2026 3:33 AM ET
Data refreshes hourly during market hours. Next update: 4:33 AM
Data refreshes hourly during market hours. Next update: 4:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DCTH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$83 | 62 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$82 | 64 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 62 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$107 | 62 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 67 BUY |
